M. Ostrowska

Publications69
h-index13
Citations738
Highly Influential Citations22
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Kubica
  • 357 Publications • 5,180 Citations
  • J. Siller-Matula
  • 216 Publications • 6,237 Citations
  • E. Navarese
  • 237 Publications • 5,835 Citations
  • A. Kubica
  • 95 Publications • 1,349 Citations
  • Publications
  • Influence
Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial
TLDR
Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction and all three methods of platelet reactivity assessment showed a stronger antiplatelet effect in the placebo group and a greater prevalence of high platelets reactivity in patients receiving morphine.
View PDF
Metallacrown-based compounds: Applications in catalysis, luminescence, molecular magnetism, and adsorption
View via Publisher
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial
TLDR
This study is expected to provide essential evidence-based data on the impact of morphine on the absorption of ticagrelor in patients with myocardial infarction as well as to shed some light on the suspected connection between morphine use and antiplatelet activity in the same group of patients.
View on Springer
Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.
TLDR
It was shown, that desferrioxamine and deferasirox are antiproliferative agents active in several types of cancer and very potent compounds with possible use as anticancer drugs are thiosemicarbazones.
View on PubMed
New directions for pharmacotherapy in the treatment of acute coronary syndrome
TLDR
Introduction of cangrelor and ezetimibe, and potentially future recognition of proprotein convertase subtilisin/kexin type 9 antibodies, are likely to alter the landscape of ACS pharmacotherapy.
View on Taylor & Francis
Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?
TLDR
Results of the first clinical trials on chloroquine and hydroxychloroquine in the treatment of COVID-19 are shown, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself.
View PDF
Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
TLDR
Identification of ACS patients who have the highest odds of HPR during the initial phase of treatment with ticagrelor is facilitated, and who could potentially benefit from alternative treatment strategies are facilitated.
View on Springer
Glucose transporters in cattle - a review.
TLDR
In this review, genomic structure and function of the bovine glucose transporters are described and intra-species comparative analyses o the amino acid identities of glucose transporter proteins is also described, as well as the information on the nucleotide sequence polymorphisms in the b beef glucose transporter genes.
Expression of PC, PCK1, PCK2, LDHB, FBP1 and G6PC genes in the liver of cows in the transition from pregnancy to lactation.
TLDR
The effect of the transition of dairy cows from pregnancy to lactation on the expression of genes encoding enzymes involved in hepatic glucose metabolism was studied and the LDHB gene showed the highest expression level.
A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated,…
TLDR
It is hypothesized that reduction of the ticagrelor maintenance dose 1 month after acute coronary syndrome and its continuation until 12 months after ACS may improve adherence to antiplatelet treatment due to better tolerability compared with the standard dose of ticgrelor.
View PDF
...
...